- Home
- ODV vs SPRY Comparison
ODV vs SPRY Comparison
Compare ODV & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ODV | SPRY |
|---|---|---|
| Founded | 2005 | 2015 |
| Country | Canada | United States |
| Employees | 102 | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 853.2M | 788.5M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | ODV | SPRY |
|---|---|---|
| Price | $2.62 | $8.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $40.00 |
| AVG Volume (30 Days) | ★ 3.8M | 1.8M |
| Earning Date | 08-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $84,278,000.00 |
| Revenue This Year | N/A | $87.40 |
| Revenue Next Year | $2.70 | $81.64 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.95 | $6.66 |
| 52 Week High | $4.80 | $18.63 |
Technical Indicators
Market Signals| Indicator | ODV | SPRY |
|---|---|---|
| Relative Strength Index (RSI) | 36.87 | 53.78 |
| Support Level | $2.44 | $8.61 |
| Resistance Level | $2.91 | $9.51 |
| Average True Range (ATR) | 0.17 | 0.62 |
| MACD | -0.02 | 0.11 |
| Stochastic Oscillator | 23.94 | 60.93 |
Price Performance
Historical ComparisonAbout ODV Osisko Development Corp.
Osisko Development Corp is a mineral exploration and development company engaged in the acquisition, exploration, and development of precious metals resource properties in North America. The company is focused on exploring and developing its mining assets, including the Cariboo Gold Project in British Columbia, the San Antonio gold project in Mexico, and the Trixie test mine in the USA. The Company projects include Cariboo Gold Project, Tintic Project, and Exploration.
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.